Laureate Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laureate Pharma - overview
Established
2002
Location
Princeton, NJ, US
Primary Industry
Biotechnology
About
Laureate Pharma is dedicated to the development and manufacturing of biopharmaceutical products, emphasizing innovative solutions for complex pulmonary diseases, while ensuring high-quality standards and effective treatments for the healthcare sector. Founded in 2002, Laureate Pharma operates in Princeton, US, specializing in biopharmaceutical services. The company was acquired by Gallus BioPharmaceutical in October 2013. It has completed a total of 4 deals, with its latest funding round being a Growth round that raised USD 20.
00 mn, bringing the total amount raised to USD 20. 00 mn. The company collaborates with investors like Saints Capital to further its operations. Laureate Biopharmaceutical Services focuses on developing and manufacturing a diverse range of pharmaceutical products, especially complex pulmonary drugs.
Their comprehensive technological processes include fine chemical synthesis and formulation of finished dosage forms, aimed at delivering effective treatments to healthcare providers and pharmacies in New Jersey. Collaborations with companies such as Arius Pharmaceuticals enhance their innovative product offerings, further solidifying their position in the biopharmaceutical market. In the most recent year, Laureate Biopharmaceutical Services reported a revenue of USD 7. 40 mn.
Revenue is primarily generated through direct sales to healthcare providers and pharmacies, facilitated through B2B partnerships. Their focus on quality assurance and compliance with GMP standards underpins their transactional relationships and reputation within the healthcare sector. Laureate Pharma is strategizing for future growth by designing new pharmaceutical products aimed at complex pulmonary conditions. The recent investment from the Growth round will support these initiatives and assist in expanding into new markets, though specific regions or launch dates have not been disclosed.
Following the acquisition by Gallus BioPharmaceutical in October 2013, the company is positioned to leverage new opportunities in the biopharmaceutical landscape.
Current Investors
Ridgemont Equity Partners, Gallus Biopharmaceuticals
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.laureatepharma.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Laureate Pharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Laureate Pharma | - | ||||||||
| Growth | Completed | Laureate Pharma | - | ||||||||
| Secondary Buyout | Completed | Laureate Pharma | - | ||||||||
| Buyout | Completed | Laureate Pharma | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.